Jump to content

Aurobindo Pharma

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 132.183.56.57 (talk) at 00:48, 24 March 2024. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

{{Infobox company | name = Aurobindo Pharma Limited | logo = File:Aurobi | logo_padding = | image = | image_size = | image_alt = | image_caption = | native_name = | native_name_lang = | romanized_name = | former_name = | type = Public | traded_as = NSE: AUROPHARMA
BSE: 524804 | ISIN = | industry = Pharmaceuticals

| products =

  • Pharmaceuticals
  • generic drugs
  • [[over-the-couwp-content/uploads/2020/08/Aurobindo-Pharma-Limited-Annual-Report-2019-20.pdf |archive-date=2020-08-13 |url-status=dead}}</ref> }}

    | fate = | predecessor = | successor = | founded = 1986 | founders = V. Ramprasad Reddy[1]
    K. Nityananda Reddy[1] | defunct = | hq_location = Hyderabad, Telangana, India | hq_location_city = | hq_location_country = | num_locations = | num_locations_year = | area_served = | brands = | production = | production_year = | services = | revenue = Increase ₹23,290 crore (US$2.8 billion) (2020)[2] | operating_income = Increase ₹4,063 crore (US$490 million) (2020)[2] | net_income = Increase ₹2,844 crore (US$340 million) (2020)[2] | assets = Increase ₹28,926 crore (US$3.5 billion) (2020)[2] | equity = Increase ₹16,751 crore (US$2.0 billion) (2020)[2] | owner = cs/annual-reports/aurobindo-ar-2016-17.pdf |archive-date=21 January 2022 |url-status=dead}}</ref> | num_employees_year = 2020 | parent = | divisions = | subsid = | module = | ratio = | rating = | footnotes = | website = www.aurobindo.com }} l]] pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics.[3] The company markets these products in over 125 countries.[3] Its marketing partners include AstraZeneca[4] and Pfizer.[5]

    Company

    Aurobindo Pharma clindamycin capsules

    The company commenced operations in 1988–89 with a single unit manufacturing semi-synthetic penicillin (SSP) in Puducherry.[6] Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. Aurobindo Pharma also has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.

    Aurobindo Pharma features among the top 10 companies in India in terms of consolidated revenues.[3] Aurobindo exports to over 125 countries with more than 70% of its revenues derived out of international operations.

    In 2014, Aurobindo purchased the generic operations of Actavis in 7 Western European countries for $41 million.[7][8]

    Business expansion

    Aurobindo Pharma plans to expand its product portfolio with high-va products in US

</ref>

In 2017, Aurobindo Pharma inked a pact to acquire Portugal’s Generis Farmaceutica SA from Magnum Capital Partners for a consideration of €135 million.[9] It also acquired four biosimilar products from Swiss firm TL Biopharmaceutical AG.[10]

Aurobindo Pharma Ltd. signed a definitive agreement to purchase the Apotex businesses in Poland, the Czech Republic, the Netherlands, Spain and Belgium. The agreement is conditional on the receipt of competition clearances for the transaction by the Dutch and Polish authorities. As part of the proposed sale, Apotex will enter into a transitional manufacturing and supply arrangement with Aurobindo to support the ongoing growth plans of these businesses.[11]

In December 2016, 20 American attorneys general filed a civil complaint accusing Aurobindo Pharma of a coordinated scheme to artificially maintain high prices for a generic antibiotic and diabetes drug. The complaint alleged price collusion schemes between six pharmaceutical firms including informal gatherings, telephone calls, and text messages.[12]

On 11 April 2018, Aurobindo was featured in the Dutch documentary television program Zembla.[13] It details accusations against

Recalls

See also: Valsartan § recalls, and Angiotensin II receptor blocker § recalls

In 2018,[14] and 2019,[15] Aurobindo Pharma USA recalled tablets containing valsartan due to the detection of N-Nitrosodiethylamine (NDEA) which is a probable human carcinogen.

In November 2019, Aurobindo Pharma USA recalled ranitidine tablets, capsules, and syrup due to the detection of unacceptable levels of N-nitrosodimethylamine (NDMA).[16]

See also

References

  1. ^ a b "Aurobindo Overview".
  2. ^ a b c d e "Aurobindo Pharma Ltd. Financial Statements". moneycontrol.com.
  3. ^ a b c "Aurobindo Pharma Ltd: Company Overview, History, Contacts | Brand India Pharma". www.brandindiapharma.in. Retrieved 15 October 2019.
  4. ^ "Aurobindo Pharma signs supply pact with AstraZeneca", The Economic Times, 6 September 2010
  5. ^ "Pfizer, Astra deals to drive Aurobindo Pharma’s growth", The Economic Times, 5 November 2010
  6. ^ "Know 10 largest Pharmaceutical Companies in India". Edu Dwar. 12 January 2023. Retrieved 28 July 2023.
  7. ^ "Aurobindo Buys Actavis' European Operations". News: Industry Watch. Gen. Eng. Biotechnol. News (paper). Vol. 34, no. 4. 15 February 2014. p. 10.
  8. ^ "Aurobindo To Buyout Actavis' EU Ops". Bloomberg TV India. Retrieved 20 January 2014.
  9. ^ PTI (7 January 2017). "Aurobindo Pharma to acquire Portugal's Generis for €135 million". mint. Retrieved 12 April 2021.
  10. ^ Trivedi, Isha (10 February 2017). "Aurobindo Pharma buys 4 biosimilar products from TL Biopharmaceutical". mint. Retrieved 12 April 2021.
  11. ^ Limited, Aurobindo Pharma. "Aurobindo Signs a Definitive Agreement to Acquire Apotex' Businesses in Poland, Czech Republic, the Netherlands, Spain and Belgium". PR Newswire. Retrieved 12 April 2021. {{cite web}}: |last= has generic name (help)
  12. ^ Thomas, Katie (15 December 2016). "20 States Accuse Generic Drug Companies of Price Fixing". The New York Times. Retrieved 16 December 2016.
  13. ^ "'Manufacturer of Dutch medicines exploit workers and pollute the environment' - Zembla - BNNVARA". Zembla (in Dutch). Retrieved 12 April 2021.
  14. ^ "Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Consumer Level Recall of 80 Lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP, Due to the Detection of NDEA (N-Nitrosodiethylamine) Impurity". Food and Drug Administration. 31 December 2018. Aurobindo Pharma USA, Inc. is conducting a voluntary recall of 80 lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product. The impurity detected in the finished drug product is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.Public Domain This article incorporates text from this source, which is in the public domain.
  15. ^ "AurobindoPharma USA, Inc. Initiates a Voluntary Nationwide Consumer Level Recall Expansion of 38 Lots of Amlodipine Valsartan Tablets USP and Valsartan Tablets, USP due to the detection of NDEA (N-Nitrosodiethylamine) Impurity". Food and Drug Administration. 1 March 2019. AurobindoPharma USA, Inc. and Acetris Health LLC. Are conducting a voluntary recall expansion of 39 lots of Valsartan and Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product. This recall is an expansion of the recall initiated 12/31/18 The impurity detected in the finished drug product is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.Public Domain This article incorporates text from this source, which is in the public domain.
  16. ^ "Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Consumer Level Recall of 38 Lots of Ranitidine Tablets 150mg, Ranitidine Capsules 150mg, Ranitidine Capsules 300mg and Ranitidine Syrup 15mg/mL Due to the Detection of NDMA (Nitrosodimethylamine) Impurity". U.S. Food and Drug Administration (FDA). 6 November 2019. Archived from the original on 11 November 2019. Retrieved 10 November 2019. Aurobindo Pharma USA, Inc. is conducting a voluntary recall of 1 lot of Ranitidine Tablets 150mg to the retail level and 37 lots of Ranitidine Capsules 150mg, Ranitidine Capsules 300mg and Ranitidine Syrup 15mg/mL to the consumer level due to the detection of NDMA (Nitrosodimethylamine) Impurity in the finished product. The impurity detected is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.Public Domain This article incorporates text from this source, which is in the public domain.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Aurobindo_Pharma&oldid=1215255120"